Literature DB >> 3300327

Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study.

G I Greenwald, D P Tashkin, H Gong, M Simmons, S Duann, D E Furst, P Clements.   

Abstract

Most patients with progressive systemic sclerosis (PSS) exhibit lung involvement. However, the natural history of lung disease in PSS remains poorly defined. To evaluate lung function over time in PSS, a battery of lung function tests were prospectively performed serially between 1973 and 1982 in 61 patients with PSS. Functional indexes of restriction (vital capacity and total lung capacity) and diffusion impairment (diffusing capacity) showed greater-than-expected annual rates of change. Male subjects showed a trend toward faster declines in forced vital capacity, forced expired volume in one second, total lung capacity, and functional residual capacity and a more rapid increase in static recoil pressure at 90 percent of total lung capacity than did female subjects. Nonsmokers had greater rates of decline in total lung capacity and static lung compliance (but not in forced vital capacity or diffusing capacity) and a greater rate of increase in static recoil pressure than did current and former smokers. Level of lung function at initial study visit, age, race, and chlorambucil therapy had no significant effect on the annual rates of change in lung function, whereas longer duration of disease prior to study entry was associated with a slower annual decrease in lung volumes. Between the first and last visits (mean interval 3.1 years, maximum nine years), the frequency of abnormality in pulmonary function test results showed significant change only in the diffusing capacity (60 percent increasing to 82 percent) and static lung compliance (40 percent increasing to 54 percent), whereas the frequency of respiratory symptoms showed little change. These findings indicate an overall indolent progression of PSS-related lung disease, with substantial individual variability.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300327     DOI: 10.1016/0002-9343(87)90501-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease.

Authors:  Athanasios Koutroumpas; Athanasios Ziogas; Ioannis Alexiou; Georgia Barouta; Lazaros I Sakkas
Journal:  Clin Rheumatol       Date:  2010-06-10       Impact factor: 2.980

2.  Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease.

Authors:  E Renzoni; P Rottoli; G Coviello; M G Perari; M Galeazzi; M Vagliasindi
Journal:  Clin Rheumatol       Date:  1997-11       Impact factor: 2.980

3.  A longitudinal study of pulmonary function in Danish patients with systemic sclerosis.

Authors:  S Jacobsen; P Halberg; S Ullman; M Høier-Madsen; J Petersen; J Mortensen; A Wiik
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

4.  When there's smoke there's…scleroderma: evidence that patients with scleroderma should stop smoking.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-01-08       Impact factor: 5.782

5.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

Review 6.  Scleroderma lung: pathogenesis, evaluation and current therapy.

Authors:  Jacob M van Laar; Jan Stolk; Alan Tyndall
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Patterns of pulmonary function in smoking and nonsmoking patients with progressive systemic sclerosis.

Authors:  Silvia A Quadrelli; Luciana Molinari; Lorena M Ciallella; Martin Bosio; Alejandro Salvado
Journal:  Rheumatol Int       Date:  2009-01-08       Impact factor: 2.631

8.  Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions.

Authors:  Paola Caramaschi; Domenico Biasi; Marcello Ferrari; Alessandro Volpe; Nicola Martinelli; Antonio Carletto; Paola Dal Forno; Lisa Maria Bambara
Journal:  Rheumatol Int       Date:  2004-02-13       Impact factor: 2.631

9.  High resolution computed tomography in systemic sclerosis. Real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalities of lung investigation.

Authors:  A Pignone; M Matucci-Cerinic; A Lombardi; R Fedi; R Fargnoli; R De Dominicis; M Cagnoni
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

10.  Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger?

Authors:  M J Abramson; A J Barnett; G O Littlejohn; M M Smith; S Hall
Journal:  Postgrad Med J       Date:  1991-07       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.